The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Here are 5 of CFRA analysts' top growth stocks that have reported at least 15% annual revenue growth in the past three years.

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...